Agenus Inc. (AGEN)
Agenus Inc. (AGEN) is a biotechnology company focused on the development of immunotherapies for cancer and infectious diseases. Founded in 1994, the company specializes in the research and development of innovative vaccine adjuvants and immune checkpoint modulators aimed at enhancing the body's immune response. Agenus's portfolio includes a range of monoclonal antibodies, vaccines, and other immunotherapeutic products targeting unmet medical needs.
Company News
The FDA is tightening survival standards in cancer research, with private investments helping to fill public funding gaps. Several biotech companies are advancing innovative immunotherapies, with Oncolytics Biotech showing promising results in pancreatic cancer treatment.
PD-(L)1 inhibitors are projected to dominate future drug sales, revolutionizing cancer care across multiple tumor types with flexible treatment approaches and promising clinical outcomes.
Agenus, a biotech company, reported its Q3 2024 earnings. The company's lead drug candidate, BOT/BAL, is showing promising results in treating various cancers, including microsatellite stable colorectal cancer. However, Agenus is facing financial challenges and is exploring strategic transactions and asset monetization to support the development of BOT/BAL.
Ligand Pharmaceuticals (LGND) has reached a new 52-week high of $103.295, reflecting the company's strong financial performance and growth potential. The company has made several strategic moves, including acquiring APEIRON Biologics and expanding its credit facility, which have contributed to its positive market performance.
Agenus Inc. (AGEN) shares plunged 58.8% after the FDA discouraged the accelerated approval pathway for the company's immunotherapy combination botensilimab (BOT) and balstilimab (BAL) in relapsed/refractory microsatellite stable colorectal cancer. The FDA cited concerns that the observed objective response rate might not translate to a survival benefit.